Comment on

• A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.

  Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. Patel SP, et al. Clin Cancer Res. 2020 May 15;26(10):2290-2296. doi: 10.1158/1078-0432.CCR-19-3356. Epub 2020 Jan 22. Clin Cancer Res. 2020. PMID: 31969335 Free PMC article. Clinical Trial.
• Ipilimumab and Nivolumab in Rare Tumors S1609: Neuroendocrine-Letter.

  Sonbol MB, Halfdanarson TR. Sonbol MB, et al. Clin Cancer Res. 2020 May 15;26(10):2433. doi: 10.1158/1078-0432.CCR-20-0443. Clin Cancer Res. 2020. PMID: 32414760 No abstract available.